US-based clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ: HOTH) announced on Wednesday that it has regained full compliance with Nasdaq's minimum bid price requirement.

Hoth has received formal notice from the Nasdaq Listing Qualifications Department confirming that its common stock had closed at or above the USD1.00 minimum bid price for 10 consecutive trading sessions, from 4 to 17 June, satisfying the requirement under Listing Rule 5550(a)(2). As a result, the compliance matter is officially closed.

"Regaining Nasdaq compliance is a major milestone for Hoth and reflects growing market confidence in our strategy and pipeline," said Robb Knie, Hoth Therapeutics CEO. "We believe our upcoming catalysts and clinical programmes position us for significant value creation in 2025."

Hoth says that it is now strategically focused on delivering key milestones across multiple therapeutic areas, including inflammatory diseases, oncology and rare diseases.